|
|||||||||||
![]() |
![]() |
||||||||||
|
SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-focused, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN® (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant . SciClones pipeline of drug ... More » Recent ReleasesMar 1, 2010 Events & PresentationsMar 16, 2010 at 11:00 AM PT Mar 9, 2010 at 3:45 PM ET |
||||||||||
| ©2010 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer. Terms of Use | Notes Regarding Forward-Looking Statements | |||||||||||